ANSWER: B

Rationale:

Beta-blockers are the established first-line pharmacological therapy for stable exertional angina in patients without contraindications. Their antianginal mechanism operates through two complementary pathways: reduction of heart rate (negative chronotropy) and reduction of myocardial contractility (negative inotropy), both of which decrease myocardial oxygen demand — the primary determinant of angina threshold. The dose titration target for antianginal efficacy is a resting heart rate of 55–60 beats per minute with adequate suppression of exercise-induced tachycardia; this target reflects the heart rate range at which oxygen supply-demand balance is optimized. Metoprolol succinate (a cardioselective beta-1 blocker) and atenolol are the agents most commonly used in this indication.

• Option A: Option A is incorrect — long-acting nitrates are effective antianginals and are commonly used in combination therapy, but they are not preferred as monotherapy first-line agents for stable exertional angina; additionally, the nitrate-free interval is required to prevent tolerance but does not make nitrate monotherapy the preferred initial choice.
• Option C: Option C is incorrect — dihydropyridine calcium channel blockers such as amlodipine produce vasodilation and can reduce afterload, but they do not reduce heart rate and may cause reflex tachycardia; they are appropriate alternatives when beta-blockers are contraindicated, not preferred over beta-blockers as initial therapy.
• Option D: Option D is incorrect — ranolazine occupies a fourth-line add-on position in stable angina treatment algorithms; it is not appropriate as first-line monotherapy despite its mechanistic rationale.
• Option E: Option E is incorrect — sublingual nitroglycerin is used for acute anginal episodes and is not appropriate as scheduled chronic prophylactic monotherapy; its short duration of action and rapid tolerance development make it unsuitable for this role.

ANSWER: D

Rationale:

When beta-blockers are contraindicated — as in significant obstructive airway disease where even cardioselective beta-1 blockers carry a risk of bronchospasm — long-acting dihydropyridine calcium channel blockers such as amlodipine are the preferred alternative first-line antianginal agents. Dihydropyridines act primarily on vascular smooth muscle calcium channels, reducing peripheral vascular resistance and afterload and producing coronary vasodilation; they have minimal direct effect on the sinoatrial node or atrioventricular conduction. This profile makes them hemodynamically safe in patients whose cardiac conduction status and left ventricular function may not be fully defined.

• Option A: Option A is incorrect — verapamil does produce significant heart rate reduction, but non-dihydropyridine agents (verapamil and diltiazem) carry meaningful negative chronotropic and dromotropic effects; in patients with unrecognized conduction disease or impaired left ventricular function, these effects can precipitate heart block or hemodynamic compromise; they are not the preferred first choice when beta-blockers must be replaced without full cardiac evaluation.
• Option B: Option B is incorrect for the same reason as option A — diltiazem's rate-lowering and conduction-slowing effects make it a second-choice agent relative to dihydropyridines in this substitution context; additionally, the claim that it is preferred "regardless of baseline left ventricular function" is clinically dangerous, as non-dihydropyridines are contraindicated in patients with significantly reduced ejection fraction.
• Option C: Option C is incorrect — short-acting nifedipine is specifically avoided in stable angina because its rapid vasodilation triggers reflex sympathetic activation and tachycardia, which worsens myocardial oxygen demand and can paradoxically precipitate ischemia; it has no role as a beta-blocker substitute in stable angina management.
• Option E: Option E is incorrect — the distinction between dihydropyridine and non-dihydropyridine agents is clinically important and not merely a matter of preference; the two subclasses have fundamentally different hemodynamic and electrophysiological profiles that determine safety in individual patients.

ANSWER: A

Rationale:

Organic nitrate tolerance is a well-characterized pharmacodynamic phenomenon that limits the long-term efficacy of continuous nitrate therapy. The dominant mechanism involves depletion of free sulfhydryl groups in vascular smooth muscle and, critically, oxidative inactivation of mitochondrial aldehyde dehydrogenase 2 (ALDH2) — the enzyme that bioactivates glyceryl trinitrate (nitroglycerin) and other organic nitrates to generate nitric oxide. Reactive oxygen species generated during nitrate biotransformation progressively impair ALDH2 activity; as enzyme capacity falls, nitric oxide generation declines and vasorelaxation is lost. The nitrate-free interval of 10–14 hours per day allows ALDH2 activity and vascular sulfhydryl groups to recover, restoring drug responsiveness. The once-daily morning dosing of ISMN extended-release is specifically designed to exploit this principle — the extended-release profile produces therapeutic concentrations during waking hours while the overnight period serves as the nitrate-free interval.

• Option B: Option B is incorrect — nitrate tolerance is a pharmacodynamic phenomenon, not a pharmacokinetic one; isosorbide mononitrate is already the active form (not a prodrug requiring hepatic activation) and does not undergo significant first-pass metabolism; switching to sublingual nitroglycerin would not address tolerance and is inappropriate for chronic prophylaxis.
• Option C: Option C is incorrect — while reflex sympathetic activation does occur with nitrate-induced vasodilation and can contribute to secondary hemodynamic counterregulation, it is not the primary mechanism of nitrate tolerance; alpha-1 blockers are not used to prevent nitrate tolerance and are not part of standard antianginal management for this purpose.
• Option D: Option D is incorrect — isosorbide mononitrate is the active metabolite, not the prodrug; isosorbide dinitrate (ISDN) is the prodrug that requires hepatic conversion to ISMN; progressive enzyme saturation of a converting enzyme is not the mechanism of ISMN tolerance.
• Option E: Option E is incorrect — guanylate cyclase desensitization does not represent an irreversible process without a preventive strategy; the nitrate-free interval reliably restores guanylate cyclase responsiveness; describing tolerance as unpreventable is inaccurate.

ANSWER: C

Rationale:

Beta-blockers are contraindicated in vasospastic angina regardless of cardioselectivity. The pathophysiology of coronary vasospasm in this condition involves exaggerated alpha-adrenergic-mediated vasoconstriction of epicardial coronary arteries. Under normal physiological conditions, beta-2 adrenergic receptor stimulation on coronary smooth muscle provides a vasodilatory counterbalance to alpha-adrenergic tone. When beta-receptors are blocked, this vasodilatory influence is removed, and alpha-adrenergic vasoconstriction is left unopposed — a pharmacological state that can provoke or intensify coronary spasm. This risk applies to both non-selective beta-blockers (which block beta-1 and beta-2 equally) and cardioselective agents; even "cardioselective" beta-1 blockers have meaningful beta-2 activity at clinical doses and are not safe in vasospastic angina.

• Option A: Option A is incorrect — beta-blockers are not appropriate for vasospastic angina for the mechanistic reasons stated above; nocturnal vagal tone does contribute to spasm episodes, but this is not a rationale for beta-blocker use.
• Option B: Option B is incorrect — the distinction between cardioselective and non-selective beta-blockers does not remove the contraindication in vasospastic angina; cardioselective agents retain sufficient beta-2 activity at clinical doses to impair coronary vasodilatory tone; all beta-blockers should be avoided in this condition.
• Option D: Option D is incorrect — while endothelin-1 and thromboxane A2 do contribute to the pathophysiology of coronary spasm, adrenergic receptor blockade does have a clinically significant effect on coronary tone; the claim that beta-blockers have no effect in this setting is pharmacologically inaccurate.
• Option E: Option E is incorrect — the contraindication to beta-blockers in vasospastic angina is not conditional on concurrent use of calcium channel blockers; it applies as monotherapy and in combination.

ANSWER: E

Rationale:

Calcium channel blockers are the cornerstone of pharmacological management of vasospastic angina and are supported by the strongest clinical evidence for this indication. Both dihydropyridine agents (amlodipine, long-acting nifedipine) and non-dihydropyridine agents (diltiazem, verapamil) are effective because the fundamental mechanism — blockade of L-type voltage-gated calcium channels in coronary vascular smooth muscle — is shared across the class. Calcium influx through L-type channels is the final common pathway for smooth muscle contraction and sustained spasm; channel blockade directly prevents the calcium-dependent contractile event regardless of the triggering stimulus (adrenergic, endothelin, or acetylcholine-mediated). High-dose CCB therapy achieves spasm prevention in the large majority of patients and is the established first-line pharmacological backbone for this condition.

• Option A: Option A is incorrect — long-acting nitrates are a useful adjunctive therapy in vasospastic angina but are not the primary backbone agent; chronic nitrate monotherapy is limited by tolerance development, and the claim that nitrates "completely prevent spasm" overstates their efficacy relative to CCBs.
• Option B: Option B is incorrect — ranolazine's mechanism targets late sodium current in cardiomyocytes, not coronary smooth muscle; it has no established role as a primary agent in vasospastic angina management.
• Option C: Option C is incorrect — ivabradine reduces sinus node firing rate through If channel blockade in the sinoatrial node; it has no direct effect on coronary vascular smooth muscle tone and no established role in vasospastic angina.
• Option D: Option D is incorrect — while endothelial dysfunction does contribute to vasospastic angina pathophysiology, ACE inhibitors are not established first-line therapy for this indication; they do not directly prevent smooth muscle calcium influx and have not demonstrated the degree of spasm prevention seen with CCBs in clinical practice.

ANSWER: B

Rationale:

In patients with heart failure with reduced ejection fraction (HFrEF, defined as LVEF below 40%), the selection of calcium channel blocker subclass is critically important. Non-dihydropyridine CCBs — verapamil and diltiazem — exert clinically significant negative inotropic effects in addition to their effects on heart rate and atrioventricular conduction; in a patient with already-compromised systolic function, this negative inotropy can precipitate acute decompensation and is a recognized contraindication. In contrast, long-acting dihydropyridine CCBs — specifically amlodipine and felodipine — act predominantly on peripheral vascular smooth muscle L-type calcium channels, producing afterload reduction without meaningful direct myocardial depression. The PRAISE-1 and PRAISE-2 trials evaluated amlodipine specifically in patients with advanced heart failure (including ischemic and non-ischemic cardiomyopathy) and demonstrated that amlodipine did not worsen heart failure outcomes; it is accordingly the dihydropyridine of choice when a CCB is needed in HFrEF.

• Option A: Option A is incorrect — verapamil's negative inotropic effect is not beneficial in HFrEF; it represents an additional contractile depression superimposed on already-impaired myocardium; verapamil is contraindicated in patients with significant systolic dysfunction.
• Option C: Option C is incorrect — the safety distinction in HFrEF is between dihydropyridines and non-dihydropyridines as a class, not between individual chemical subtypes within non-dihydropyridines; diltiazem shares the contraindication with verapamil in reduced ejection fraction due to its negative inotropic and dromotropic effects.
• Option D: Option D is incorrect — amlodipine and felodipine are specifically approved for use in patients with HFrEF when antianginal or antihypertensive therapy is needed; blanket contraindication of all CCBs in this population is inaccurate.
• Option E: Option E is incorrect — short-acting nifedipine is specifically avoided in stable angina and heart failure because its rapid peripheral vasodilation triggers reflex sympathetic activation and tachycardia, worsening myocardial oxygen demand; it is not preferred in any angina population and is particularly inappropriate in HFrEF.

ANSWER: A

Rationale:

Beta-blockers occupy a uniquely privileged position in the post-myocardial infarction setting because they carry two simultaneous evidence-based indications: antianginal efficacy and post-infarction mortality reduction. The mortality benefit of beta-blockers post-MI is independent of their antianginal effect and has been established through multiple randomized trials demonstrating reductions in sudden cardiac death (through suppression of malignant ventricular arrhythmias), non-fatal reinfarction, and adverse ventricular remodeling. Metoprolol succinate and carvedilol are the agents with the strongest post-MI evidence base. This dual benefit makes beta-blockers the clear preferred first antianginal choice when patients tolerate them and do not have contraindications.

• Option B: Option B is incorrect — long-acting nitrates have not been shown in randomized trials to reduce post-MI mortality; they are useful antianginals but lack the survival benefit that makes beta-blockers the preferred agent in this population; the claim of comparable or superior mortality benefit is not supported by evidence.
• Option C: Option C is incorrect — dihydropyridine CCBs do not carry a demonstrated post-MI mortality benefit; while they are appropriate antianginals in patients who cannot tolerate beta-blockers, they are not preferred over beta-blockers as initial therapy in post-MI patients with preserved or mildly reduced ejection fraction; the claim of "superior survival benefit" is inaccurate.
• Option D: Option D is incorrect — the MERLIN-TIMI 36 trial evaluated ranolazine in non-ST-elevation acute coronary syndromes and did not demonstrate a significant reduction in the primary endpoint of cardiovascular death, MI, or recurrent ischemia; ranolazine reduced recurrent ischemia but not mortality; it is not a first-line agent in the post-MI setting.
• Option E: Option E is incorrect — ivabradine (studied in the BEAUTIFUL and SHIFT trials) demonstrated benefit in patients with HFrEF and elevated resting heart rate on background beta-blocker therapy; it does not carry a mortality reduction benefit that exceeds or replaces beta-blockers in the post-MI setting; it is not a first-line antianginal agent in this population.

ANSWER: D

Rationale:

The interaction between beta-blockers and hypoglycemia in insulin-requiring diabetic patients is a clinically important pharmacological concept, but it does not constitute an absolute contraindication to beta-blocker use. The key distinction lies in the autonomic pathways mediating different hypoglycemic symptoms. Tachycardia, tremor, anxiety, and palpitations — the adrenergically mediated warning signs of hypoglycemia — are blunted or suppressed by beta-receptor blockade. However, diaphoresis (sweating) is mediated by cholinergic sympathetic fibers that release acetylcholine onto sweat gland muscarinic receptors; this pathway is entirely unaffected by beta-adrenergic blockade and remains intact as a hypoglycemic warning sign. Additionally, non-selective beta-blockers impair hepatic glycogenolysis (a beta-2-mediated process) and can prolong hypoglycemia recovery, which is a relevant secondary concern with non-selective agents. In clinical practice, beta-blockers remain appropriate in diabetic patients with compelling indications (post-MI, angina, HFrEF) provided patients are counseled about the altered symptom profile — specifically, to recognize sweating as the preserved warning sign rather than relying on tachycardia.

• Option A: Option A is incorrect — diaphoresis is preserved during beta-blockade because it is cholinergically mediated; the claim that all autonomic warning signs are suppressed is pharmacologically inaccurate, and blanket contraindication is not appropriate clinical guidance.
• Option B: Option B is incorrect — beta-blockers do not stimulate insulin secretion; beta-2 receptors in pancreatic beta cells mediate insulin release, and beta-blocker effects on this pathway suppress rather than stimulate insulin secretion, though this is not the dominant clinical concern.
• Option C: Option C is incorrect — while non-selective beta-blockers do impair hepatic glycogenolysis to a greater degree than cardioselective agents, neither class carries an absolute contraindication in diabetic patients on insulin; the risk profile warrants clinical awareness and counseling, not avoidance.
• Option E: Option E is incorrect — glucagon is secreted by pancreatic alpha cells, not hepatic Kupffer cells; the mechanism attributed to cardioselective beta-1 blockade in this option is anatomically and pharmacologically fabricated.

ANSWER: C

Rationale:

Several principles govern antianginal drug selection and initiation in elderly patients. First, short-acting dihydropyridine calcium channel blockers — particularly immediate-release nifedipine — are specifically contraindicated in stable angina management regardless of age and are especially problematic in elderly patients. The rapid blood pressure fall produced by immediate-release nifedipine triggers a brisk baroreceptor-mediated sympathetic reflex that increases heart rate, plasma catecholamines, and myocardial oxygen demand — a response that can paradoxically precipitate or worsen ischemia. In elderly patients, this reflex tachycardia is superimposed on reduced baroreceptor sensitivity and impaired autonomic buffering, making hemodynamic swings less predictable and orthostatic hypotension more likely. Second, aging is associated with reduced hepatic blood flow and CYP enzyme activity, reduced renal clearance, decreased albumin binding (for some drugs), and increased body fat-to-lean ratio — pharmacokinetic changes that collectively increase drug exposure and prolong effect duration. Third, elderly patients have greater sensitivity to hemodynamic perturbations, making gradual titration from low starting doses an essential safety principle.

• Option A: Option A is incorrect — pharmacokinetic differences in aging are clinically significant for cardiovascular drugs and directly influence starting dose, titration interval, and risk of adverse effects; standard adult dosing without modification is not appropriate in the elderly.
• Option B: Option B is incorrect — while long-acting nitrates are reasonable antianginal agents in the elderly, they do carry a risk of orthostatic hypotension (particularly on standing), which is amplified in this population; the claim that no dose titration is necessary is inaccurate.
• Option D: Option D is incorrect — beta-blockers are not contraindicated by age alone; they remain appropriate in elderly patients with angina (especially post-MI) provided there are no specific contraindications such as significant conduction disease or decompensated heart failure; age-related reduction in receptor density does reduce maximal pharmacological response but does not render beta-blockers ineffective.
• Option E: Option E is incorrect — verapamil's pharmacokinetics are significantly affected by aging; hepatic first-pass metabolism of verapamil declines with age, increasing oral bioavailability and plasma concentrations; standard adult doses without modification carry an increased risk of bradycardia, heart block, and constipation in elderly patients.

ANSWER: E

Rationale:

Isosorbide mononitrate (ISMN) is metabolized predominantly in the liver to inactive metabolites that are then excreted renally; the parent compound and its metabolites do not accumulate to pharmacologically active levels in CKD, and no dose adjustment is required even in advanced renal impairment. This pharmacokinetic profile makes long-acting nitrates among the most renally safe antianginal agents available — a clinically useful property in CKD patients who face complex polypharmacy challenges. The important practical caveat is hemodynamic: CKD patients are frequently volume-depleted due to diuretic use, dietary restriction, or impaired sodium handling, and nitrate-induced vasodilation can produce orthostatic hypotension in this context; monitoring is warranted but does not require dose modification.

• Option A: Option A is incorrect — while some beta-blockers (atenolol, nadolol) are renally eliminated and require dose adjustment in CKD, others (metoprolol, carvedilol, bisoprolol) undergo predominant hepatic elimination and do not require dose reduction; the class as a whole is not contraindicated in CKD, and the claim of unmanageable accumulation is inaccurate.
• Option B: Option B is incorrect — isosorbide mononitrate does not require dose reduction in CKD; active nitrate metabolite accumulation causing prolonged hypotension in renal impairment is not an established pharmacokinetic concern for ISMN; this description does not reflect the drug's actual pharmacokinetic behavior.
• Option C: Option C is incorrect — amlodipine undergoes extensive hepatic metabolism with minimal renal elimination; it does not accumulate in CKD and requires no dose adjustment based on GFR; this is one of the pharmacokinetic advantages of amlodipine in patients with renal impairment.
• Option D: Option D is incorrect — ranolazine does require caution in severe renal impairment and is not recommended in end-stage renal disease (ESRD on dialysis), but the specific dose reduction threshold described (GFR below 30 with mandatory 500 mg twice-daily cap) does not accurately reflect the ranolazine prescribing information; the primary concern is QTc prolongation from potential metabolite accumulation, but dose adjustment in moderate CKD (stage 3-4) is not mandated by prescribing information in the same categorical way as described.

ANSWER: B

Rationale:

The combination of a beta-blocker and a long-acting dihydropyridine calcium channel blocker such as amlodipine is one of the most pharmacologically rational and clinically utilized dual antianginal strategies. The mechanistic basis is complementarity: beta-blockers (via beta-1 receptor blockade) reduce heart rate and contractility but can increase peripheral vascular resistance (due to unopposed alpha-adrenergic tone) and raise left ventricular end-diastolic pressure; dihydropyridine CCBs reduce peripheral vascular resistance and afterload through vascular smooth muscle L-type calcium channel blockade, offsetting the beta-blocker-mediated vasoconstriction. Conversely, dihydropyridines — especially in their short-acting forms — trigger baroreceptor-mediated reflex sympathetic activation and tachycardia; beta-blocker co-administration blunts this reflex, allowing the vasodilatory benefit of the CCB without the ischemia-worsening tachycardia. The net result is additive antianginal efficacy through mechanistically distinct and mutually counterbalancing hemodynamic effects.

• Option A: Option A is incorrect — combining metoprolol with verapamil represents a pharmacologically dangerous combination rather than a rational one; both agents independently slow sinoatrial node discharge and impair atrioventricular conduction, and their additive effects on chronotropy and dromotropy create a substantial risk of symptomatic bradycardia, high-degree AV block, and hemodynamic compromise; this combination is generally avoided.
• Option C: Option C is incorrect — isosorbide mononitrate + beta-blocker is a rational and commonly used combination; nitrates reduce preload and left ventricular wall stress while the beta-blocker reduces heart rate and contractility; the combination is not unsafe due to additive hypotension in routine outpatient use with appropriate titration.
• Option D: Option D is incorrect — metoprolol's membrane-stabilizing (local anesthetic-like) activity is a pharmacological property present at very high concentrations but is not its therapeutic mechanism at clinical doses; ranolazine's late sodium current inhibition operates through an entirely different molecular mechanism; there is no clinically meaningful pharmacodynamic overlap that would produce additive bradycardia through this proposed pathway.
• Option E: Option E is incorrect — dihydropyridine CCBs and beta-blockers act through entirely distinct receptor pathways; dihydropyridines act on voltage-gated L-type calcium channels in vascular smooth muscle, while beta-blockers act on G-protein-coupled beta-adrenergic receptors in the myocardium; there is no shared receptor pathway and no redundancy; the pharmacological rationale for combining them is precisely their mechanistic distinction.

ANSWER: A

Rationale:

The combination of a beta-blocker and a non-dihydropyridine calcium channel blocker — verapamil or diltiazem — is associated with an additive risk of bradycardia and atrioventricular conduction block that warrants serious clinical caution. Both drug classes independently depress sinoatrial node automaticity and slow conduction through the atrioventricular node: beta-blockers through beta-1 receptor blockade of the cAMP-mediated pacemaker current, and verapamil/diltiazem through L-type calcium channel blockade in nodal tissue (where the action potential upstroke depends on calcium current rather than sodium current). When these mechanisms are combined, their effects on AV nodal conduction are additive. In a patient whose resting heart rate is already 58 bpm — near the lower end of the target therapeutic range for antianginal beta-blockade — adding verapamil carries a meaningful risk of producing symptomatic bradycardia (heart rate below 50 bpm) or progressing to second- or third-degree AV block. This risk is amplified in patients with pre-existing sinoatrial or atrioventricular conduction disease. For these reasons, the combination of oral beta-blocker and verapamil or diltiazem is generally avoided; when a second antianginal agent is needed in a patient already on a beta-blocker, a dihydropyridine CCB (amlodipine) is the safe alternative.

• Option B: Option B is incorrect — verapamil does not act exclusively on vascular smooth muscle; it has well-characterized direct cardiac electrophysiological effects and significant negative inotropy; the premise that both drugs act on the same vascular target is pharmacologically inaccurate.
• Option C: Option C is incorrect — atenolol undergoes minimal hepatic metabolism and is primarily renally eliminated; it is not a CYP2D6 substrate in the clinically meaningful sense; the pharmacokinetic interaction described does not occur with atenolol.
• Option D: Option D is incorrect — oral verapamil does produce clinically significant cardiac conduction effects at therapeutic doses; the distinction between oral and intravenous administration is one of rate of onset and degree, not presence or absence of cardiac effect; adding oral verapamil to a beta-blocker in a patient already at 58 bpm is not safe.
• Option E: Option E is incorrect — the primary risk of this combination is conduction-related, not coronary vasospasm; combined reduction in coronary perfusion pressure causing vasospasm is not an established or recognized mechanism of toxicity for this drug combination.

ANSWER: D

Rationale:

Microvascular angina is driven by coronary microvascular dysfunction — specifically, impaired endothelium-dependent vasodilation, increased microvascular tone, and coronary flow reserve limitation — rather than obstructive epicardial disease or spasm of large conduit vessels. The pharmacological management strategy accordingly targets endothelial function and microvascular tone. ACE inhibitors reduce angiotensin II levels, which in the coronary microcirculation would otherwise promote vasoconstriction, oxidative stress (via NADPH oxidase activation), and endothelial inflammation; by reducing these effects, ACE inhibitors improve endothelium-dependent vasodilation and have demonstrated benefit in microvascular angina in clinical studies. Statins contribute through their lipid-independent (pleiotropic) effects: they upregulate endothelial nitric oxide synthase (eNOS) activity, reduce vascular inflammation, and stabilize endothelial function — effects that address microvascular dysfunction independent of LDL cholesterol reduction. Beta-blockers are also used in microvascular angina for their heart rate-reducing effects, and calcium channel blockers have a role particularly when microvascular spasm is a component.

• Option A: Option A is incorrect — long-acting nitrates have inconsistent efficacy in microvascular angina; unlike vasospastic angina where epicardial spasm responds reliably to nitric oxide donation, the microcirculation may not respond as predictably; nitrate monotherapy does not produce complete resolution in the majority of patients and is not the cornerstone agent.
• Option B: Option B is incorrect — beta-blockers are not contraindicated in microvascular angina; they are used as part of the management strategy for their heart rate and oxygen demand-reducing effects; the concern about unopposed alpha-adrenergic vasoconstriction in the microcirculation that applies to vasospastic epicardial angina does not constitute a recognized contraindication in microvascular angina.
• Option C: Option C is incorrect — calcium channel blockers are used in microvascular angina, particularly when a vasospastic component is suspected; the claim that L-type calcium channels play no role in microvascular tone is inaccurate.
• Option E: Option E is incorrect — ranolazine is not contraindicated in microvascular angina; it has been studied in this indication (RWISE trial and others) and may reduce symptoms through its metabolic cardioprotective mechanism; the proposed mechanism of worsening perfusion pressure is pharmacologically unsupported.

ANSWER: C

Rationale:

Ranolazine inhibits the late inward sodium current (INa) in cardiomyocytes, which reduces intracellular sodium accumulation during ischemia, secondarily reduces calcium overload via the sodium-calcium exchanger, and improves diastolic relaxation and oxygen utilization efficiency. This mechanism produces antianginal benefit without affecting heart rate, blood pressure, or contractility — a profile that is genuinely useful in patients who cannot tolerate hemodynamic effects of other agents. However, despite this pharmacological rationale, ranolazine's position in treatment algorithms reflects the clinical evidence base: the CARISA and ERICA trials demonstrated antianginal efficacy as add-on therapy in patients with inadequate symptom control on conventional agents, but no randomized trial has demonstrated that ranolazine monotherapy produces superior anginal outcomes or mortality benefit compared to beta-blockers, calcium channel blockers, or long-acting nitrates as initial therapy. Current guidelines position ranolazine as a fourth-line add-on for refractory stable angina after conventional dual or triple therapy has been optimized — not as first-line monotherapy regardless of hemodynamic tolerability. The representative's argument conflates the absence of hemodynamic adverse effects with superiority of efficacy, which is a pharmacological non sequitur.

• Option A: Option A is incorrect — ranolazine is FDA-approved for chronic angina; the approved indication is specifically stable angina in patients who have not achieved adequate response to other antianginal therapies; the statement that it is not approved for angina is factually incorrect.
• Option B: Option B is incorrect — ranolazine is pharmacologically active as monotherapy; its mechanism of action does not require concurrent beta-blockade; it can reduce angina episodes as a single agent, and its trial evidence includes add-on therapy to both beta-blockers and CCBs.
• Option D: Option D is incorrect — ranolazine is not contraindicated in reduced ejection fraction; the MERLIN-TIMI 36 trial included patients with acute coronary syndromes and varying ejection fractions; ejection fraction alone does not restrict ranolazine use.
• Option E: Option E is incorrect — ranolazine has not been withdrawn from major markets; it remains approved and available; post-marketing QTc-associated mortality has not been established as a basis for market withdrawal.

ANSWER: E

Rationale:

Chronic beta-blocker therapy produces compensatory upregulation of beta-adrenergic receptors in response to persistent pharmacological blockade. When the drug is abruptly discontinued, these sensitized and numerically increased receptors are suddenly exposed to normal circulating catecholamines (and the substantially elevated perioperative catecholamine surge), producing an exaggerated adrenergic response. Clinically, this manifests as rebound tachycardia, hypertension, and heightened myocardial oxygen demand — a combination that significantly increases the risk of myocardial ischemia and infarction in patients with underlying coronary artery disease. The perioperative setting compounds this risk: surgery itself produces a major catecholamine surge, and the combination of receptor upregulation and perioperative sympathetic activation creates a window of extreme ischemic vulnerability. Current perioperative guidelines uniformly recommend continuing beta-blockers through surgery in patients who are chronically established on them; the drug should be administered orally preoperatively or converted to intravenous metoprolol if the patient cannot take oral medications postoperatively.

• Option A: Option A is incorrect — while metoprolol's half-life does allow it to remain active for some hours after a missed dose, the critical issue is not residual drug effect but the receptor upregulation that has developed during chronic therapy; this upregulation produces rebound upon dose cessation regardless of when the last dose was taken; abrupt discontinuation is not safe on this basis.
• Option B: Option B is incorrect — beta-blockers do not suppress parathyroid hormone through beta-1 receptor mechanisms; the proposed mechanism of hypercalcemia and calcium overload is pharmacologically fabricated and has no basis in established physiology.
• Option C: Option C is incorrect — the development of coronary collateral circulation does not abolish dependence on heart rate reduction for ischemia prevention; patients with well-controlled angina remain at risk for rebound ischemia upon abrupt beta-blocker discontinuation regardless of disease duration.
• Option D: Option D is incorrect — malignant hyperthermia is a pharmacogenetic disorder triggered by volatile anesthetics and succinylcholine, mediated by RYR1 mutations causing uncontrolled skeletal muscle calcium release; it has no mechanistic relationship to beta-blocker discontinuation, and beta-blockers do not mask or modify the malignant hyperthermia syndrome.

ANSWER: B

Rationale:

The distinction between continuing established chronic beta-blocker therapy and initiating beta-blockers de novo in the perioperative period is a critical and well-supported guideline recommendation. For patients who are chronically on beta-blockers — particularly those with coronary artery disease, prior MI, or heart failure — perioperative continuation is consistently recommended because abrupt withdrawal carries the rebound ischemia risk described in Question 15. If oral administration is not possible on the morning of surgery (NPO status, postoperative ileus), intravenous metoprolol or alternative delivery methods are used to maintain coverage. The concern about intraoperative bradycardia and hypotension is real but manageable with standard anesthetic technique; it does not outweigh the risk of rebound ischemia from discontinuation in a patient with established coronary disease.

• Option A: Option A is incorrect — beta-blocker continuation in established patients does not produce unacceptable intraoperative cardiac arrest risk; intraoperative hemodynamic management routinely accounts for beta-blocker effects; the risk framing is inverted from the evidence base.
• Option C: Option C is incorrect — a 72-hour perioperative drug withdrawal window does not exist in current guidelines and would not produce receptor downregulation; receptor upregulation from chronic beta-blocker use persists beyond a 72-hour window and the withdrawal period would expose the patient to exactly the rebound risk the question is designed to avoid.
• Option D: Option D is incorrect — current guidelines do not recommend beta-blocker withdrawal based on resting heart rate below a threshold; the criterion for perioperative continuation is chronic established use with a compelling indication, not heart rate range on the morning of surgery.
• Option E: Option E is incorrect — the POISE trial did demonstrate that perioperative beta-blocker initiation reduced non-fatal MI rates but simultaneously increased 30-day mortality (predominantly from stroke and hemodynamic compromise) in patients not previously on beta-blockers; the trial results explicitly do not support de novo initiation in all surgical patients; the guideline distinction between continuation (supported) and initiation (not supported for most patients) is an important clinical lesson from this trial.

ANSWER: A

Rationale:

The combination of a beta-blocker and a long-acting nitrate is mechanistically complementary in a specific and clinically important way. Beta-blockers reduce heart rate (via sinoatrial node suppression) and contractility (via reduced beta-1-mediated cAMP generation), both of which lower myocardial oxygen demand. However, the bradycardia produced by beta-blockade prolongs diastolic filling time and, in some patients, increases left ventricular end-diastolic volume and pressure (LVEDP), raising myocardial wall stress — a mechanism that partially offsets the oxygen demand reduction. Additionally, beta-blockade reduces myocardial emptying in patients with impaired function, further elevating filling pressures. Long-acting nitrates address exactly this liability: by dilating venous capacitance vessels, they reduce venous return, lower right and left ventricular filling pressures, and decrease LVEDP and wall stress. In the opposite direction, nitrate-induced arterial and venous vasodilation activates baroreceptors and produces a reflex sympathetic discharge that increases heart rate — a counter-therapeutic effect for angina; beta-blocker co-administration blunts this reflex tachycardia, allowing the nitrate to provide its vasodilatory antianginal benefit without the ischemia-worsening heart rate increase. The two agents thus form a mutually correcting pair with additive antianginal efficacy through independent mechanisms.

• Option B: Option B is incorrect — isosorbide mononitrate is not a CYP3A4 substrate and does not inhibit CYP enzymes; the pharmacokinetic interaction described does not exist.
• Option C: Option C is incorrect — beta-blockers do not cause clinically significant hyperkalemia through beta-2-mediated Na/K-ATPase inhibition in the clinical dose range; and long-acting nitrates are not diuretics and do not lower serum potassium through diuresis; the mechanism described is pharmacologically fabricated.
• Option D: Option D is incorrect — nitric oxide activates soluble guanylate cyclase to produce cGMP, not cAMP; cGMP and cAMP are distinct second messenger systems; guanylate cyclase and adenylyl cyclase are separate enzymes; there is no cross-activation mechanism of the type described, and sensitization of beta-1 receptors through nitrate signaling does not occur.
• Option E: Option E is incorrect — there is no procedural requirement to demonstrate two-drug antianginal failure before revascularization can be considered; revascularization assessment is triggered by symptom burden, evidence of significant ischemia, or anatomy — not adherence to a specific drug sequencing rule.

ANSWER: D

Rationale:

Ivabradine is a selective inhibitor of the hyperpolarization-activated cyclic nucleotide-gated (HCN) channel, specifically the HCN4 isoform that predominates in sinoatrial node pacemaker cells. This channel — also termed the If (funny current) channel — conducts an inward sodium and potassium current that activates upon membrane hyperpolarization at the end of each action potential; this inward depolarizing current is the primary driver of spontaneous diastolic depolarization (phase 4) in sinoatrial pacemaker cells, determining the rate at which the threshold for the next action potential is reached. By blocking this channel, ivabradine slows the rate of phase 4 depolarization, extending the time to threshold and reducing heart rate in a dose-dependent manner. Critically, this mechanism has no effect on myocardial contractility (since HCN4 is not expressed at significant levels in ventricular cardiomyocytes), no effect on peripheral vascular tone, and no effect on atrioventricular conduction at therapeutic concentrations. This hemodynamically neutral heart rate reduction makes ivabradine suitable in a patient with asthma in whom beta-blockers are contraindicated — the mechanism bypasses adrenergic receptors entirely and carries no bronchospasm risk.

• Option A: Option A is incorrect — ivabradine does not block L-type calcium channels; its mechanism is specific to HCN channels; confusing ivabradine with calcium channel blockers represents a fundamental mechanistic error.
• Option B: Option B is incorrect — ivabradine is not a beta-adrenergic receptor blocker of any selectivity profile; it does not interact with beta-1 or beta-2 receptors; its mechanism is entirely independent of adrenergic receptor pharmacology.
• Option C: Option C is incorrect — ivabradine does not inhibit late inward sodium current; it acts on HCN channels, which are structurally and pharmacologically distinct from voltage-gated sodium channels; the proposed mechanism is pharmacologically fabricated.
• Option E: Option E is incorrect — ivabradine has no beta-adrenergic receptor activity, partial or otherwise; it carries no bronchospasm risk; it is not classified as a beta-blocker with partial agonist activity in any pharmacological or regulatory framework.

ANSWER: C

Rationale:

For stable exertional angina, the target resting heart rate during beta-blocker therapy is 55–60 beats per minute. This range reflects the point at which the drug's negative chronotropic and negative inotropic effects have meaningfully reduced baseline myocardial oxygen demand while avoiding excessive bradycardia that could compromise diastolic filling, cardiac output, or patient tolerability. Mechanistically, achieving a resting heart rate of 55–60 bpm matters not only for baseline oxygen demand reduction but because it sets the starting point for exertional heart rate elevation: a patient with a resting rate of 72 bpm (as in the case above) may reach 120–130 bpm with moderate exertion — a range at which myocardial oxygen demand exceeds supply across a significant coronary stenosis; a patient with a resting rate of 58 bpm on adequate beta-blockade will reach a lower peak exertional heart rate, with the angina threshold rate (the heart rate at which ischemia occurs) potentially remaining unmet during ordinary activity. The functional antianginal goal is therefore suppression of exertional tachycardia, and the resting rate target is a dosing guide toward this goal.

• Option A: Option A is incorrect — a target of 40–45 bpm is below the therapeutic range and represents excessive bradycardia; at this heart rate range, cardiac output is compromised, and the claim that subendocardial perfusion is "fully restored" in severe stenosis overstates what heart rate reduction alone can achieve.
• Option B: Option B is incorrect — a blanket target below 50 bpm is not supported by antianginal guidelines and represents aggressive over-titration; uptitration without symptomatic monitoring at this level carries unacceptable risk of hemodynamic compromise.
• Option D: Option D is incorrect — beta-blocker dosing for angina is not calculated as a percentage of age-predicted maximum heart rate; the 82 bpm figure derived from this formula is above the therapeutic antianginal target and does not reflect established dosing guidance.
• Option E: Option E is incorrect — heart rate monitoring is an essential component of beta-blocker dosing for stable angina and is not limited to patients with atrial fibrillation; the resting heart rate target of 55–60 bpm is a standard antianginal dosing guideline.

ANSWER: E

Rationale:

Peripheral edema is one of the most common adverse effects of dihydropyridine calcium channel blockers and is dose-dependent, occurring in up to 10–15% of patients on amlodipine 10 mg daily. The mechanism is purely local hemodynamic: dihydropyridines dilate precapillary arterioles in the dependent extremities more than they dilate postcapillary venules, creating an imbalance in Starling forces across the capillary bed — increased hydrostatic pressure drives fluid into the interstitial space. This process occurs without expansion of total body sodium or plasma volume; BNP is normal, there is no pulmonary congestion, and the JVP is not elevated — all of which confirm the absence of fluid overload. Because total body fluid is not expanded, diuretics have no pharmacological basis for resolving this edema; they will produce volume contraction and reflex neurohumoral activation without addressing the underlying hemodynamic cause. The correct management approach is: (1) dose reduction of amlodipine if antianginal or antihypertensive control permits, (2) switching to a non-dihydropyridine CCB or a different drug class, or (3) recognizing that concurrent beta-blocker use can partially mitigate dihydropyridine-induced edema by blunting the additional reflex vasodilation triggered by arteriolar dilation.

• Option A: Option A is incorrect — amlodipine does not stimulate aldosterone secretion through renal renin-angiotensin effects in a manner that would cause peripheral edema; this is pharmacologically fabricated.
• Option B: Option B is incorrect — amlodipine-associated edema is not a hypersensitivity reaction and is not histamine-mediated; it does not respond to antihistamines; this description does not represent the established mechanism.
• Option C: Option C is incorrect — amlodipine does not cause glomerular hyperfiltration producing nephrotic-range proteinuria; this mechanism is not established for dihydropyridine CCBs; furosemide would not worsen glomerular filtration in this context.
• Option D: Option D is incorrect — amlodipine's edema mechanism is not sodium retention through renal efferent arteriole effects; diuretics do not effectively treat CCB-associated edema precisely because total body sodium is not expanded; this option presents the physiological framing that leads to the prescribing error the question is designed to correct.

ANSWER: B

Rationale:

Nitrates play a well-defined adjunctive role in the management of vasospastic angina. Sublingual nitroglycerin is highly effective for aborting acute spasm episodes: it generates nitric oxide (via ALDH2 bioactivation), which activates soluble guanylate cyclase in epicardial coronary smooth muscle, increases intracellular cGMP, activates protein kinase G, and promotes myosin light chain dephosphorylation and smooth muscle relaxation — directly reversing the pathological vasoconstriction. All patients with vasospastic angina should have sublingual nitroglycerin available for breakthrough episodes. Long-acting nitrates (isosorbide mononitrate, isosorbide dinitrate) can be added to the CCB backbone for patients with breakthrough episodes despite high-dose CCB therapy, providing additional vasodilatory coverage. However, they occupy an adjunctive — not primary — role for two reasons: (1) tolerance develops with continuous nitrate use and limits long-term efficacy unless a nitrate-free interval is maintained; and (2) CCBs have a stronger and more consistent clinical evidence base for chronic spasm prevention.

• Option A: Option A is incorrect — nitrates are not contraindicated in vasospastic angina; nitrate-induced systemic vasodilation does reduce coronary perfusion pressure modestly, but the direct epicardial coronary smooth muscle relaxation effect far outweighs any perfusion pressure concern; nitrates are standard acute treatment for vasospastic episodes.
• Option C: Option C is incorrect — there are no established guidelines recommending CCB withdrawal after 3 months of spasm freedom with substitution of nitrate monotherapy; CCBs are continued as backbone therapy for chronic vasospastic angina; premature discontinuation risks spasm recurrence.
• Option D: Option D is incorrect — nitroglycerin is effective in vasospastic angina regardless of the initiating vasoconstrictor stimulus (thromboxane A2, endothelin, acetylcholine, or adrenergic); the mechanism of relaxation — cGMP-mediated smooth muscle relaxation — is downstream of the receptor-level stimulus and overrides the contractile signal effectively.
• Option E: Option E is incorrect — long-acting nitrates are not listed as equivalent first-line backbone therapy to CCBs in vasospastic angina guidelines; CCBs have the stronger evidence base for primary prevention of spasm and are the established pharmacological backbone; nitrates are adjuncts, not equals.

ANSWER: A

Rationale:

The decision to refer a patient with stable angina for coronary angiography and revascularization assessment is driven by two parallel pathways: symptom pathway and prognostic pathway. The symptom pathway applies when angina remains limiting despite adequate trial of two or more antianginal drug classes at appropriate doses — as in this patient, who is on a beta-blocker, a dihydropyridine CCB, and a long-acting nitrate at reasonable doses and continues to have angina limiting his activity to less than one block. This represents maximally optimized conventional triple therapy; adding ranolazine or ivabradine as a fourth agent is a reasonable option, but continued pharmacological escalation in the face of clear functional limitation is not required before revascularization is considered. The prognostic pathway is separate from symptoms: non-invasive testing revealing a large ischemic territory (typically defined as greater than 10% of myocardium), severely impaired coronary flow reserve, or high-risk anatomical findings (left main stenosis, proximal LAD stenosis with reduced FFR) constitutes an independent indication for revascularization regardless of symptom burden, because revascularization in these settings reduces cardiovascular events beyond medical therapy alone.

• Option B: Option B is incorrect — there is no guideline requirement to exhaust four distinct drug classes before referral; the ISCHEMIA trial clarified the role of optimal medical therapy versus revascularization, but it did not establish a sequential drug-class exhaustion requirement; persistent limiting symptoms on adequate dual or triple therapy is a recognized referral threshold.
• Option C: Option C is incorrect — while CCS class informs symptom severity documentation, CCS Class IV is not required for revascularization consideration; CCS Class II or III with functional limitation on optimal medical therapy is an appropriate indication for angiographic assessment.
• Option D: Option D is incorrect — stable angina without a recent infarction is a recognized indication for revascularization when symptoms are limiting on medical therapy or when prognostic criteria are met; multiple revascularization procedures (PCI, CABG) have established indications for stable angina; the claim that mortality reduction has not been shown in any trial is an oversimplification that ignores CABG trial data in specific anatomical subsets.
• Option E: Option E is incorrect — there is no guideline-specified requirement for ST depression exceeding 2 mm at heart rate below 100 bpm as a necessary and exclusive threshold for angiographic referral; functional capacity, symptom burden, imaging ischemia assessment, and clinical judgment collectively inform the referral decision.